Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-01T03:46:37.082Z Has data issue: false hasContentIssue false
  • English
  • Français

Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas

Published online by Cambridge University Press:  07 November 2014

Bernardo Dell'Osso  and
A. Carlo Altamura
Get access Rights & Permissions [Opens in a new window]

Abstract

The duration of untreated illness (DUI), defined as the interval between the onset of a psychiatric disorder and the administration of the first pharmacological treatment, has been increasingly investigated in the last decade as a predictor of outcome across different psychiatric conditions including schizophrenia and psychotic disorders (duration of untreated psychosis), and mood and anxiety disorders. Converging evidence indicates that a prolonged DUI may be viewed as a negative prognostic factor in schizophrenia and increasing data point toward a similar conclusion in mood and anxiety disorders. Through a Medline search, the present article highlights the role of the DUI in this group of psychiatric disorders, focusing on social and psychopathological determinants of the DUI, as well as the clinical consequences related to a longer DUI in terms of outcome. Hypotheses on neurobiological mechanisms underpinning outcome differences in relation to a prolonged DUI are provided and methodological limitations related to the assessment of the DUI in published studies and clinical practice discussed. Finally, given that DUI is supposed to be a potentially modifiable prognostic factor, intervention programs aimed to reduce this variable are briefly considered and discussed.

Type
Review Article
Information
CNS Spectrums , Volume 15 , Issue 4 , April 2010 , pp. 238 - 246
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Malla, A, Norman, R, McLean, T, Scholten, D, Townsend, L. A Canadian programme for early intervention in non-affective psychotic disorders. Aust N Z J Psychiatry. 2003; 37: 407–413.CrossRefGoogle ScholarPubMed
2. Melle, I, Larsen, TK, Haahr, U et al. , Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry. 2004; 61: 143–150.CrossRefGoogle ScholarPubMed
3. Melle, I, Larsen, TK, Haahr, U et al. , Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008; 65: 634–640.CrossRefGoogle ScholarPubMed
4. Jackson, D, Lawoyin, R, Gaynor, K et al. , Is the duration of untreated psychosis temporally stable? Eur Psychiatry. 2008; 23: 97–99.CrossRefGoogle ScholarPubMed
5. Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P, Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005; 62: 975–983.CrossRefGoogle ScholarPubMed
6. Perkins, DO, Gu, H, Boteva, K, Lieberman, JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005; 162: 1785–1804.CrossRefGoogle ScholarPubMed
7. Clarke, M, Whitty, P, Browne, S et al. , Suicidality in first episode psychosis. Schizophr Res. 2006; 86: 221–225.CrossRefGoogle ScholarPubMed
8. Freidl, M, Piralic Spitzl, S, Aigner, M. How depressive symptoms correlate with stigma perception of mental illness. Int Rev Psychiatry. 2008; 20: 510–514.CrossRefGoogle ScholarPubMed
9. Schimmelmann, BG, Huber, CG, Lambert, M, Cotton, S, McGorry, PD, Conus, P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res. 2008; 42: 982–990.CrossRefGoogle Scholar
10. Jeppesen, P, Petersen, L, Thorup, A et al. , The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008; 38: 1157–1166.CrossRefGoogle ScholarPubMed
11. Goldberg, JF, Ernst, CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002; 63: 985–991.CrossRefGoogle ScholarPubMed
12. Mantere, O, Suominen, K, Leppämäki, S, Valtonen, H, Arvilommi, P, Isometsä, E. The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study (JoBS). Bipolar Disord. 2004; 6: 395–405.CrossRefGoogle ScholarPubMed
13. Bauer, M, Juckel, G, Correll, CU, Leopold, K, Pfennig, A. Diagnosis and treatment in the early illness phase of bipolar disorders. Eur Arch Psychiatry Clin Neurosci. 2008; 258(Suppl 5): 50–54.CrossRefGoogle ScholarPubMed
14. Dell'Osso, B, Mundo, E, Albano, A et al. , Duration of untreated illness in anxiety and mood disorders. Presented at the 16th AEP Congress, Apr 5-9, 2008, Nice (F). Eur Psychiatry. 2008; 23(Supp 2): S369.CrossRefGoogle Scholar
15. Singh, SP. Outcome measures in early psychosis; relevance of duration of untreated psychosis. Br J Psychiatry. 2007; 50: s58–63.CrossRefGoogle ScholarPubMed
16. Bechard-Evans, L, Schmitz, N, Abadi, S, Joober, R, King, S, Malla, A. Determinants of help-seeking and system related components of delay in the treatment of first-episode psychosis. Schizophr Res. 2007; 96: 206–214.CrossRefGoogle ScholarPubMed
17. Jané-Llopis, E, Hosman, C, Jenkins, R, Anderson, P. Predictors of efficacy in depression prevention programmes. Meta-analysis. Br J Psychiatry. 2003; 183: 384–397.CrossRefGoogle ScholarPubMed
18. Ellison-Wright, I, Glahn, DC, AR, Laird, Thelen, SM, Bullmore, E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation metaanalysis. Am J Psychiatry. 2008; 165: 1015–1023.CrossRefGoogle ScholarPubMed
19. Salisbury, DF, Kuroki, N, Kasai, K, Shenton, ME, McCarley, RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry. 2007; 64: 521–529.CrossRefGoogle ScholarPubMed
20. Lawrie, SM, McIntosh, AM, Hall, J, Owens, DG, Johnstone, EC, Johnstone, EC. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull. 2008; 34: 330–340.CrossRefGoogle ScholarPubMed
21. Hulshoff Pol, HE, Kahn, RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008; 34: 354–366.CrossRefGoogle ScholarPubMed
22. Cahn, W, Rais, M, Stigter, FP et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2009; 19: 147–151.CrossRefGoogle ScholarPubMed
23. Harris, MG, Henry, LP, Harrigan, SM et al. , The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005; 79: 85–93.CrossRefGoogle ScholarPubMed
24. Goldberg, TE, Burdick, KE, McCormack, J et al. , Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr Res. 2009; 107: 262–266.CrossRefGoogle ScholarPubMed
25. Lappin, JM, Morgan, KD, Morgan, C et al. , Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res. 2007; 95: 103–110.CrossRefGoogle ScholarPubMed
26. Simonsen, E, Friis, S, Haahr, U et al. , Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand. 2007; 116: 54–61.CrossRefGoogle ScholarPubMed
27. Barnes, TR, Leeson, VC, Mutsatsa, SH, Watt, HC, Hutton, SB, Joyce, EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008; 193: 203–209.CrossRefGoogle ScholarPubMed
28. Altamura, AC, Bassetti, R, Sassella, F, Salvadori, D, Mundo, E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res. 2001; 52: 29–36.CrossRefGoogle ScholarPubMed
29. Altamura, AC, Bassetti, R, Bignotti, S, Pioli, R, Mundo, E. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res. 2003; 60: 47–55.CrossRefGoogle ScholarPubMed
30. Coyle, JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996; 3: 241–253.CrossRefGoogle ScholarPubMed
31. Olney, JW, Farber, NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995; 52: 998–1007.CrossRefGoogle ScholarPubMed
32. Altamura, AC, Bobo, WV, Meltzer, HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007; 22: 249–267.CrossRefGoogle ScholarPubMed
33. Häfner, H, Löffler, W, Maurer, K, Hambrecht, M, an der Heiden, W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999; 100: 105–118.CrossRefGoogle ScholarPubMed
34. Morgan, C, Abdul-Al, R, Lappin, JM et al. , Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br J Psychiatry. 2006; 189: 446–452.CrossRefGoogle ScholarPubMed
35. Koolschijn, PC, van Haren, NE, Lensvelt-Mulders, GJ, Hulshoff Pol, HE, Kahn, RS. Brain volume abnormalities in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009; 30: 3719–3735.CrossRefGoogle ScholarPubMed
36. Altamura, AC, Dell'Osso, B, Vismara, S, Mundo, E. May duration of untreated illness influence the long-term course of major depressive disorder? Eur Psychiatry. 2008; 23: 92–96.CrossRefGoogle ScholarPubMed
37. Scott, J, Eccleston, D, Boys, R. Can we predict the persistence of depression? Br J Psychiatry. 1992; 161: 633–637.CrossRefGoogle ScholarPubMed
38. Gormley, N, O'Leary, D, Costello, F. First admissions for depression: is the ‘no-treatment interval’ a critical predictor of time to remission? J Affect Disord. 1999; 54: 49–54.CrossRefGoogle ScholarPubMed
39. Altamura, AC, Dell'Osso, B, Mundo, E, Dell'Osso, L. Duration of untreated illness in major depressive disorder: a naturalistic study. Int J Clin Pract. 2007; 61: 1697–1700.CrossRefGoogle ScholarPubMed
40. de Diego-Adeliño, J, Portella, MJ, Puigdemont, D, Pérez-Egea, R, Alvarez, E, Pérez, V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord. 2010; 120: 221–225.CrossRefGoogle Scholar
41. Grunze, H, Kasper, S, Goodwin, G et al. , World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002; 3: 115–124.CrossRefGoogle ScholarPubMed
42. Suppes, T, Dennehy, EB, Hirschfeld, RM et al. , Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005; 66: 870–886.CrossRefGoogle Scholar
43. Arvilommi, PKS, Suominen, Mantere, OK, Leppämäki, S, Valtonen, H, Isometsä, ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry. 2007; 68: 102–110.CrossRefGoogle ScholarPubMed
44. Suominen, K, Mantere, O, Valtonen, H et al. , Early age at onset of bipolar disorder is associated with more severe clinical features but delayed treatment seeking. Bipolar Disord. 2007; 9: 698–705.CrossRefGoogle ScholarPubMed
45. Altamura, AC, Dell'Osso, B, Berlin, HA, Buoli, M, Bassetti, R, Mundo, E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psych Clin Neurosci. In press.Google Scholar
46. Baethge, C, Gruschka, P, Smolka, MN et al. , Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psychiatry Neurosci. 2003; 28: 355–361.Google ScholarPubMed
47. Baethge, C, Tondo, L, Bratti, IM et al. , Prophylaxis latency and outcome in bipolar disorders. Can J Psychiatry. 2003; 48: 449–457.CrossRefGoogle ScholarPubMed
48. Norrholm, SD, Ouimet, CC. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse. 2001; 42: 151–163.CrossRefGoogle ScholarPubMed
49. Davidson, RJ, Pizzagalli, D, Nitschke, JB, Putnam, K. Depression: perspective from affective neuroscience. Annu Rev Psychol. 2002; 53: 545–574.CrossRefGoogle ScholarPubMed
50. Bremner, JD, Narayan, M, Anderson, ER, Staib, LH, Miller, HL, Charney, DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000; 157: 115–118.CrossRefGoogle ScholarPubMed
51. Videbech, P, Ravnkilde, B. Hippocampal volume and depression. A meta-analysis of MRI studies. Am J Psychiatry. 2004; 161: 1957–1966.CrossRefGoogle ScholarPubMed
52. Bremner, JD, Vythilingam, M, Vermetten, E et al. , Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry. 2002; 51: 273–279.CrossRefGoogle ScholarPubMed
53. Hamidi, M, Drevets, WC, Price, JL. Glial reduction in amygdale is due to oligodendrocytes. Biol Psychiatry. 2004; 55: 563–569.CrossRefGoogle Scholar
54. Cotter, D, Mackay, D, Landau, S, Kerwin, R, Everall, I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001; 58: 545–553.CrossRefGoogle ScholarPubMed
55. Drevets, WC, Price, JL, Simpson, JR Jr et al. , Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997; 386: 824–827.CrossRefGoogle ScholarPubMed
56. Ongür, D, Drevets, WC, Price, JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998; 95: 13290–13295.CrossRefGoogle ScholarPubMed
57. Jacobs, BL, Praag, H, Gage, FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000; 5: 262–269.CrossRefGoogle ScholarPubMed
58. Manji, HK, Duman, RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001; 35: 5–49.Google ScholarPubMed
59. Duman, RS, Malberg, J, Thome, J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999; 46: 1181–1191.CrossRefGoogle ScholarPubMed
60. Duman, RS, Nakagawa, S, Malberg, J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 2001; 25: 836–844.CrossRefGoogle ScholarPubMed
61. Malberg, JE, Eisch, AJ, Nestler, EJ, Duman, RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20: 9104–9110.CrossRefGoogle ScholarPubMed
62. Malberg, JE, Duman, RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003; 28: 1562–1571.CrossRefGoogle ScholarPubMed
63. Lucassen, PJ, Fuchs, E, Czéh, B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry. 2004; 55: 789–796.CrossRefGoogle ScholarPubMed
64. Sheline, YI, Sanghavi, M, Mintun, MA, Gado, MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999; 19: 5034–5043.CrossRefGoogle Scholar
65. Sheline, YI, Gado, MH, Kraemer, HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003; 160: 1516–1518.CrossRefGoogle ScholarPubMed
66. Bienvenu, OJ, Ginsburg, GS. Prevention of anxiety disorders. Int Rev Psychiatry. 2007; 19: 647–654.CrossRefGoogle ScholarPubMed
67. Roberts, NP, Kitchiner, NJ, Kenardy, J, JI, Bisson. Systematic review and meta-analysis of multiple-session early interventions following traumatic events. Am J Psychiatry. 2009; 166: 293–301.CrossRefGoogle ScholarPubMed
68. Roberts, NP, Kitchiner, NJ, Kenardy, J, Bisson, J. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev. 2009; 3: CD006869.CrossRefGoogle Scholar
69. Zohar, J, Sonnino, R, Juven-Wetzler, A, Cohen, H. Can posttraumatic stress disorder be prevented? CNS Spectr. 2009; 14(1 Suppl 1): 44–51.Google ScholarPubMed
70. Wagner, R, Silove, D, Marnane, C, Rouen, D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord. 2006; 20: 363–371.CrossRefGoogle ScholarPubMed
71. Altamura, AC, Santini, A, Salvadori, D, Mundo, E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neumpsychiatr Dis Treat. 2005; 1: 345–347.Google ScholarPubMed
72. Hidalgo, RB, Tupler, LA, Davidson, JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007; 21: 864–872.CrossRefGoogle ScholarPubMed
73. AC, Altamura, Dell'Osso, B, D'Urso, N, Russo, M, Fumagalli, S, Mundo, E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr. 2008; 13: 415–422.Google Scholar
74. Dell'Osso, B, Buoli, M, Hollander, E, Altamura, AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatr. 2010; 11: 59–65.CrossRefGoogle ScholarPubMed
75. Marchall, M, Rathbone, J. Early intervention in Psychosis. Cochrane Database Syst Rev. 2006; 4: CD004718.CrossRefGoogle Scholar
76. Schultze-Lutter, F, Ruhrmann, S, Klosterkötter, J. Early detection of psychosis - establishing a service for persons at risk. Eur Psychiatry. 2009; 24: 1–10.CrossRefGoogle ScholarPubMed
77. Joa, I, JO, Johannessen, Auestad, B et al. , The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull. 2008; 34: 466–472.CrossRefGoogle ScholarPubMed
78. Merry, S, McDowell, H, Hetrick, S, Bir, J, Muller, N. Psychological and/or educational interventions for the prevention of depression in children and adolescents. Cochrane Database Syst Rev. 2004; 1: CD003380.CrossRefGoogle Scholar
79. Cuijpers, P, Van Straten, A, Smit, F. Preventing the incidence of new cases of mental disorders: a meta-analytic review. J Nerv Ment Dis. 2005; 193: 119–125.CrossRefGoogle ScholarPubMed
80. Horowitz, JL, Garber, J. The prevention of depressive symptoms in children and adolescents: A meta-analytic review. J Consult Clin Psychol. 2006; 74: 401–415.CrossRefGoogle ScholarPubMed
81. Sutton, JM. Prevention of depression in youth: a qualitative review and future suggestions. Clin Psychol Rev. 2007; 27: 552–571.CrossRefGoogle ScholarPubMed
82. Cuijpers, P, van Straten, A, Smit, F, Mihalopoulos, C, Beekman, A. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. Am J Psychiatry. 2008; 165: 1272–1280.CrossRefGoogle ScholarPubMed
83. Gladstone, TR, Beardslee, WR. The prevention of depression in children and adolescents: a review. Can J Psychiatry. 2009; 54: 212–221.CrossRefGoogle ScholarPubMed
84. Stice, E, Shaw, H, Bohon, C, Marti, CN, Rohde, P. A meta-analytic review of depression prevention programs for children and adolescents: factors that predict magnitude of intervention effects. J Consult Clin Psychol. 2009; 77: 486–503.CrossRefGoogle ScholarPubMed
85. Pratt, BM, Woolfenden, SR. Interventions for preventing eating disorders in children and adolescents. Cochrane Database Syst Rev. 2002; 2: CD002891.Google Scholar
86. Griffin, KW, Botvin, GJ, Nichols, TR, Doyle, MM. Effectiveness of a universal drug abuse prevention approach for youth at high risk for substance use initiation. Prev Med. 2003; 36: 1–7.CrossRefGoogle ScholarPubMed
87. Beekman, AT, Smit, F, Stek, ML, Reynolds, CF 3rd, Cuijpers, PC. Preventing depression in high-risk groups. Curr Opin Psychiatry. 2010; 23: 8–11.CrossRefGoogle ScholarPubMed